Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 7:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 1,707 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Human Immunodeficiency Virus Infection(HIV)/Acquired Immunodeficiency Syndrome (AIDS) Clear all

Conditions: Hepatitis B, Hepatitis C, HIV, HIV Infections
Interventions: NCMIT, SCMIT; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 39 Years · Male only
Enrollment: 451 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: HIV Infections, HIV Seronegativity
Interventions: MTP-PE/MF59, Env 2-3; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 1992
U.S. locations: 3
States / cities: Rochester, New York • Nashville, Tennessee • Seattle, Washington

Conditions: HIV Infection, Vaginal Atrophy, Menopause, Menopause Related Conditions, Aging, Premature Aging, Atrophic Vaginitis, Dysbiosis, Vaginitis
Interventions: Estradiol Vaginal Insert; Drug
Lead sponsor: Kerry Murphy; Other
Eligibility: 45 Years to 70 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Human Immunodeficiency Virus
Interventions: Tenofovir disoproxil fumarate/emtricitabine (TDF/FTC); Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 59 Years · Male only
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: HIV-1 Infection
Interventions: Pravastatin sodium, Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate; Drug
Lead sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections; Network
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 9
States / cities: Los Angeles, California • Torrance, California • St Louis, Missouri + 6 more

Conditions: HIV Infection, LTBI
Interventions: Dolutegravir (DTG), Isoniazid (INH), Rifapentine (RPT), Antiretroviral Therapy (ART), Pyridoxine (Vitamin B6); Drug · Dietary Supplement
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 2
States / cities: San Francisco, California • Houston, Texas

Conditions: HIV Infection
Interventions: Telmisartan; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Human Immunodeficiency Virus (HIV)
Interventions: Rilpivirine, Placebo; Drug
Lead sponsor: PATH; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 136 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 2
States / cities: Newark, New Jersey • The Bronx, New York

Conditions: Sarcoma, Kaposi, HIV Infections
Interventions: Interferon alfa-2a, Zidovudine, Interferon alfa-n1; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1990
U.S. locations: 1
States / cities: New York, New York

Conditions: Human Immunodeficiency Virus, Depression, Anxiety
Interventions: THRIVE, Treatment as Usual; Behavioral · Other
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 80 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HIV Infections, Chronic Hepatitis B
Interventions: Adefovir Dipivoxil; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Infection, Human Immunodeficiency Virus
Interventions: Ortho-Cyclen, Dolutegravir, Placebo; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Miami, Florida

Conditions: HIV Infections
Interventions: Amprenavir, Lamivudine, Zidovudine; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 18 Years and older
Enrollment: 290 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 9
States / cities: Beverly Hills, California • Washington D.C., District of Columbia • Coral Gables, Florida + 6 more

Conditions: Infection, Human Immunodeficiency Virus
Interventions: Lamivudine, Sorbitol; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: HIV-infection
Interventions: Angiotensin II Infusion; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Infection, Human Immunodeficiency Virus I
Interventions: GSK1349572, GSK2248761; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 55 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: HIV Infections
Interventions: Efavirenz, Adefovir dipivoxil, Lamivudine, Didanosine; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 13 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 5
States / cities: Beverly Hills, California • Denver, Colorado • Atlanta, Georgia + 2 more

Conditions: HIV Infection, Erythrocyte Glutathione Deficiency
Interventions: Cysteine (as n-acetylcysteine) and glycine, Cysteine/glycine; Dietary Supplement
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 21 Years to 70 Years · Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HIV, Acute HIV Infection
Interventions: Dolutegravir 50 mg, Lamivudine 300 mg, Abacavir 600 mg; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Durham, North Carolina

Conditions: HIV Infections
Interventions: VRC01, SC placebo for VRC01, IV placebo for VRC01; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 6
States / cities: Boston, Massachusetts • New York, New York • Cleveland, Ohio + 1 more

Conditions: Sexually Transmitted Diseases, Pregnancy, HIV Infections
Interventions: HIV, STI and Pregnancy Prevention Curriculum, Control Curricula; Behavioral
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 12 Years to 14 Years
Enrollment: 574 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2015
U.S. locations: 4
States / cities: Anchorage, Alaska • Phoenix, Arizona • Portland, Oregon + 1 more

Conditions: Infection, Human Immunodeficiency Virus I, HIV Infection
Interventions: GW640385, Ritonavir; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 9
States / cities: Phoenix, Arizona • San Francisco, California • Washington D.C., District of Columbia + 6 more

Conditions: HIV Infections, Alcohol Use Disorder, Violence, Gender-Based
Interventions: PrEP for WINGS, PrEP Decision Aid; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 307 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Cytomegalovirus Retinitis, HIV Infections
Interventions: Sevirumab; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1998
U.S. locations: 6
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 3 more

Search by objective public record fields.

Hepatitis B Virus (HBV) Prevention for Homeless at Risk for HBV/Hepatitis C Virus (HCV)/HIV

A Phase I Clinical Trial to Evaluate: Part A. The Safety of MTP-PE/MF59 Adjuvant Emulsion. Part B. The Safety and Immunogenicity of Env 2-3, a Yeast Derived Recombinant Envelope Protein of Human Immunodeficiency Virus-1, in Combination With MTP-PE/MF59

Accelerated Genital Tract Aging in HIV: Estradiol Clinical Trial

Biomarkers for Event-driven PrEP Adherence

Effect of HAART Vs. Statin Treatment on Endothelial Function and Inflammation/Coagulation

Drug-Drug Interactions Between Rifapentine and Dolutegravir in HIV/LTBI Co-Infected Individuals

HIV and Fat Accumulation

Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278LA, for Pre-Exposure Prophylaxis

A Study of AZT Plus Human Interferon Alpha in the Treatment of AIDS-Related Kaposi's Sarcoma

Targeting HIV Retention and Improved Viral Load Through Engagement ('THRIVE')

Lamivudine and Adefovir to Treat Chronic Hepatitis B Infection in People With and Without HIV Infection

Drug Interaction Study Between Dolutegravir and an Oral Contraceptive Containing Norgestimate and Ethinylestradiol

A Study of Retrovir and Epivir Alone or in Combination With 141W94 in HIV-Infected Patients

A Phase IV, Open Label, 4-period Cross-over Study to Investigate a Drug Interaction Between Lamivudine and Sorbitol Oral Solutions in Healthy Volunteers

Physiologic Investigation of the Renin Angiotensin Aldosterone Axis in HIV

A Drug Interaction Study Evaluating Plasma GSK2248761 and GSK1349572 Pharmacokinetics in Healthy Adult Subjects.

Safety and Effectiveness of Giving an Anti-HIV Drug Combination of Adefovir Dipivoxil Plus Didanosine Plus Efavirenz Plus Lamivudine Once Daily to HIV-Infected Patients

Role of HIV on Glutathione Synthesis and Oxidative Stress

Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV Infection

Evaluating the Safety and Drug Levels of an Antibody Against HIV in Healthy, HIV-Uninfected Adults

Internet-Based Sexual Health Education for Middle School Native American Youth

GW640385 Plus Ritonavir And NRTIs For 48 Weeks In HIV-1 Infected Adults

An Effectiveness Trial of the PrEP for WINGS Study

A Phase II/III Trial of Human Anti-CMV Monoclonal Antibody MSL 109 (MACRT)